Paper Review Records
All Paper Review Records
15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
69
days
Four decades of History & Evolution of Clinical Pharmacology at US Food and Drug Administration (FDA)– Part I: Product Quality
AuthorsMehul Mehta
Affiliations1. Division of Neuropsychiatric Products, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, USA
78
days
Four Decades of History & Evolution of Clinical Pharmacology at US Food and Drug Administration (FDA)—Part II: Dose Individualization and Approvability Evidence
AuthorsMehul Mehta
Affiliations1. Division of Neuropsychiatric Products, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, USA
131
days
Engineering and Characterisation of 3D-Printed Timolol Maleate Implants for Long-Acting Glaucoma Treatment
AuthorsFebri Annuryanti; Masoud Adhami; Eneko Larrañeta; Lalitkumar Vora; Thakur Raghu Raj Singh
Affiliations1. Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia; 2. McClay Research Centre, Medical Biology Centre, School of Pharmacy, Queen’s University Belfast, Belfast, UK
74
days
Verification of a Physiologically-based Pharmacokinetic Model for Predicting CYP3A4-mediated Simvastatin and Simvastatin Acid Drug-drug Interactions
AuthorsBridget L. Morse; Bing Han; Jeffrey J. Alberts; Maria M. Posada; Gemma L. Dickinson; Stephen D. Hall
Affiliations1. Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, USA; 2. Clinical & Quantitative Pharmacology, Vertex Pharmaceuticals, Boston, USA
118
days
Exploring a Persistent Terbinafine – CYP2D6 Interaction Using Physiologically – Based Pharmacokinetic Modeling
AuthorsDevendra Pade; Jan Wahlstrom
Affiliations1. Pharmacokinetics and Drug Metabolism, Amgen Inc., Cambridge, USA; 2. Pharmacokinetics and Drug Metabolism, Amgen Inc., Thousand Oaks, USA
128
days
Immunogenicity Assays Used in Support of Marketing Applications of Oligonucleotide Therapeutics
AuthorsCecilia Arfvidsson; Lin-Zhi Chen; Susovan Mohapatra; Kamalika Mukherjee; Pallab Pradhan; Gnana Oli Rajaraman; Arkadeep Sinha; Christopher C. Stebbins; An Zhao; Zhandong Don Zhong; Robert J. Kubiak
Affiliations1. Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, Gothenborg, Sweden; 2. Boehringer Ingelheim Pharmaceuticals, Ridgefield, USA; 3. Stoke Therapeutics, Boston, USA; 4. Regeneron Pharmaceuticals, Tarrytown, USA; 5. AstraZeneca, Gaithersburg, USA; 6. AiCuris Anti-Infective Cures AG, Wuppertal, Germany; 7. Upstream Bio, Waltham, USA; 8. Immunologix Laboratories, Tampa, USA; 9. Denali Therapeutics, South San Francisco, USA; 10. Third Arc Bio, Lower Gwynedd, USA
136
days
Dissolution Enhancement by Binding Agents: A Potential Shortcut to Improving Bioavailability?
AuthorsMaja Chronowska; Jennifer Dressman
Affiliations1. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany; 2. Engelhard Arzneimittel GmbH & Co. KG, Niederdorfelden, Germany; 3. Heraclitus Advisors Pty. Ltd., Melbourne, Australia
139
days
In Vitro Release Testing for Long Acting Injectables – a Workshop Summary Report
AuthorsTalia Flanagan; Diane Burgess; Marieta Duvnjak; Nikoletta Fotaki; Kate Harris; Krutika Meena Harish Jain; Dawen Kou; Adam McCartan; Heather Mead; Johanna Milsmann; Randy Mrsny; Vasiliki Paraskevopoulou; Sharadvi Thati; Marta Venczel; David Curran
Affiliations1. UCB Pharma SA, CMC Development Sciences, Braine L’Alleud, Belgium; 2. University of Connecticut, Department of Pharmaceutical Sciences, Storrs, USA; 3. Novartis, Analytical Research & Development, Novartis Pharma AG, Basel, Switzerland; 4. University of Bath, Department of Life Sciences, Claverton Down, UK; 5. AstraZeneca, Global Product Development, Pharmaceutical Technology & Development, Operations, Macclesfield, UK; 6. Gilead Sciences, Analytical Development and Operations, Foster City, USA; 7. Genentech, Synthetic Molecule Pharmaceutical Sciences, South San Francisco, USA; 8. Boehringer Ingelheim Pharma GmbH & Co. KG, Drug Product Development NCE, Biberach, Germany; 9. Bristol Myers Squibb, New Brunswick, USA; 10. Sanofi, Global CMC Development, Sanofi-Aventis Deutschland GmbH, Frankfurt/Main, Germany; 11. GSK, Analytical Development, Collegeville, USA
178
days
Immunogenicity in Approved Adeno-Associated Virus-Based Gene Therapies: A Framework for a Tailored Assessment Strategy
AuthorsChing-Ha Lai; Susan C. Irvin; Laura I Salazar-Fontana; Christine Grimaldi; Boris Gorovits; Yuanxin Xu; Michael A. Partridge
Affiliations1. Bioanalytical Sciences, Regeneron Pharmaceuticals, Inc., Tarrytown, United States of America; 2. LAIZ Regulatory Science Consulting Sàrl, Lausanne, Switzerland; 3. Intellia Therapeutics, Cambridge, United States of America
151
days
Hand-Held Raman Spectroscopy for Paracetamol Assay in Solution for Infusion: Expanding the Capabilities of Process Analytical Technologies
AuthorsJoão Henriques; Thomas De Beer; Catarina Cardoso; Vera Moura; Carla Vitorino
Affiliations1. Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Coimbra, Portugal; 2. Laboratórios Basi, Parque Industrial Manuel Lourenço Ferreira, Mortágua, Portugal; 3. Basinnov Life Sciences, Unipessoal LDA, Lisbon, Portugal; 4. Laboratory of Pharmaceutical Process Analytical Technology, Department of Analytics, Ghent University, Ghent, Belgium; 5. Coimbra Chemistry Centre, Institute of Molecular Sciences – IMS, Department of Chemistry, University of Coimbra, Coimbra, Portugal
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days